Tesamorelin 20mg

Molecular structure

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It retains the 44-residue peptide framework associated with GHRH while incorporating a trans-3-hexenoyl modification at the amino terminus.

The chain contains peptide bonds, ionizable side chains, and multiple groups capable of hydrogen bonding. Its length and distribution of charged residues influence the balance between intramolecular interactions and interactions with the solvent.

The terminal modification changes the chemical properties of the amino terminus. It is part of the molecule's identity, rather than an unrelated excipient.

Physicochemical properties

Tesamorelin's charge distribution depends on the protonation state of its ionizable groups. Its solubility and conformational behavior depend on the solvent and solution conditions. As with other peptides, chemical degradation may involve hydrolysis, oxidation of susceptible residues, or other sequence-dependent modifications.

Biochemical mechanisms

Its established molecular target is the GHRH receptor, a G-protein-coupled receptor. Ligand binding can activate Gs-dependent signaling, stimulate adenylyl cyclase, and increase intracellular cyclic AMP.

This receptor-level mechanism is distinct from downstream biological outcomes, which can depend on receptor abundance, cellular context, and the activity of other signaling proteins.

Scientific evidence

The peptide's sequence relationship to GHRH, terminal modification, and receptor pharmacology are well characterized. A particular sample's identity and purity still require analytical verification.

Tesamorelin is supplied strictly for research use only and is not intended for human or animal consumption, clinical application, diagnostic use, or therapeutic purposes.